Drugs /

evofosfamide

Back to Drugs List

Overview

Generic Name(s):
hypoxia-activated prodrug th-302, hap th-302, and th-302
NCI Definition [1]:
A hypoxia-activated prodrug of the cytotoxin bromo-isophosphoramide mustard (Br-IPM) conjugated with 2-nitroimidazole, with potential antineoplastic activity. When exposed to hypoxic conditions, such as those found in hypoxic tumors, the 2-nitroimidazole moiety of evofosfamide is reduced. This releases the DNA-alkylating Br-IPM moiety, which introduces intra- and inter-strand DNA crosslinks in nearby cells; the crosslinks inhibit both DNA replication and cell division, and may lead to apoptosis of cells in the tumor. The inactive form of the prodrug is stable under normoxic conditions, which may limit systemic toxicity.

Clinical Trials

View Clinical Trials for evofosfamide

Evofosfamide has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating evofosfamide, 1 is phase 1 (1 open).

HPV Negative is the most frequent biomarker inclusion criterion for evofosfamide clinical trials.

Head and neck squamous cell carcinoma, melanoma, and pancreatic carcinoma are the most common diseases being investigated in evofosfamide clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Evofosfamide
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating evofosfamide and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
hap th-302, hypoxia-activated prodrug th-302, th-302
NCIT ID [1]:
C71722

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.